Related Experiment Video
Updated: Apr 15, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Perioperative management of direct oral anticoagulants: not much evidence but several different approaches]
Abstract:
New oral anticoagulants (NOACs) are a major step forward in the field of anticoagulation. As a consequence, the number of patients treated with NOACs that have to undergo surgery constantly increases. The optimal management of such patients is not clearly determined so far as scientifically established data are lacking. A first proposal is to mimic the perioperative management of patients on vitamin-K antagonists. When the risk of perioperative bleeding is low, NOAC intake is stopped 24 hours before surgery. If the risk of postoperative hemorrhage is moderate or high, NOAC treatment is interrupted 5 days before surgery with a low molecular weight heparin bridging whenever necessary. A second option is based on pharmacokinetic data. When the risk of perioperative bleeding is low, NOAC intake is stopped the day before surgery. If the risk of perioperative bleeding is higher, NOAC intake is suspended for 5 half lives before surgery, 48-72 hours or more. This interruption should be for a longer period in the presence of renal failure. When an unforeseen surgery is needed, the procedure must be delayed as late as possible. In case of emergency, non specific pro-hemostatic agents such as prothrombin complexes or recombinant factor VIIa have not strongly proven useful and must only be used in last ditch effort.
Insights
Managing patients on new oral anticoagulants (NOACs) before surgery lacks clear guidelines. Current strategies involve stopping NOACs 24 hours to 5 days prior, with bridging therapy considered for high bleeding risks.
Area of Science:
- Pharmacology and Therapeutics
- Cardiovascular Medicine
- Surgical Management
Context:
- Increasing use of novel oral anticoagulants (NOACs) in patients requiring surgery.
- Lack of established guidelines for perioperative management of patients on NOACs.
- Need for evidence-based strategies to balance thrombotic and bleeding risks.
Purpose:
- To review and propose perioperative management strategies for patients on NOACs.
- To provide guidance on NOAC interruption timing and bridging therapy.
- To address the management of unforeseen surgeries and emergency situations.
Summary:
- Two main approaches for NOAC management: mimicking vitamin-K antagonist protocols or using pharmacokinetic data.
- Strategies involve stopping NOACs 24 hours (low bleeding risk) to 5 days (high bleeding risk) before surgery, with potential low molecular weight heparin bridging.
- Pharmacokinetic-based interruption involves stopping NOACs based on half-lives, longer in renal impairment. Emergency use of pro-hemostatic agents is a last resort.
Impact:
- Aims to provide clinicians with practical options for managing NOACs perioperatively.
- Facilitates safer surgical interventions in patients on anticoagulation therapy.
- Highlights the need for further research to establish definitive guidelines.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
01:22Aneurysm IV: Nursing Management
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:30Venous Thrombosis IV: Nursing Management
01:23Peripheral Artery Disease V: Postoperative Nursing Management